Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.

Julio Alejandro Lamprea-MontealegreErin MaddenSri Lekha TummalapalliChi D ChuCarmen A PeraltaYuxian DuRakesh SinghSheldon X KongDelphine S TuotMichael G ShlipakMichelle M Estrella

Published in: Diabetes care (2022)

Among a large cohort of patients with T2DM, prescription of SGLT2i and GLP1-RA was low in those with CKD. We observed a "risk-treatment paradox," whereby patients with higher risk of adverse outcomes were less likely to receive these therapies.

Keyphrases

chronic kidney disease
end stage renal disease
rheumatoid arthritis
disease activity
ankylosing spondylitis
metabolic syndrome
combination therapy
replacement therapy